JP2025098190A5 - - Google Patents
Info
- Publication number
- JP2025098190A5 JP2025098190A5 JP2025052922A JP2025052922A JP2025098190A5 JP 2025098190 A5 JP2025098190 A5 JP 2025098190A5 JP 2025052922 A JP2025052922 A JP 2025052922A JP 2025052922 A JP2025052922 A JP 2025052922A JP 2025098190 A5 JP2025098190 A5 JP 2025098190A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- cancer
- dose
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1707864.3A GB201707864D0 (en) | 2017-05-16 | 2017-05-16 | Platinum-reistant cancer treatment |
| GB1707864.3 | 2017-05-16 | ||
| US201762513627P | 2017-06-01 | 2017-06-01 | |
| US62/513,627 | 2017-06-01 | ||
| JP2019562653A JP7627393B2 (ja) | 2017-05-16 | 2018-05-16 | 白金耐性癌の治療 |
| PCT/IB2018/053428 WO2018211433A1 (en) | 2017-05-16 | 2018-05-16 | Platinum-resistant cancer treatment |
| JP2023018285A JP7658995B2 (ja) | 2017-05-16 | 2023-02-09 | 白金耐性癌の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018285A Division JP7658995B2 (ja) | 2017-05-16 | 2023-02-09 | 白金耐性癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025098190A JP2025098190A (ja) | 2025-07-01 |
| JP2025098190A5 true JP2025098190A5 (https=) | 2025-09-30 |
Family
ID=59201547
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562653A Active JP7627393B2 (ja) | 2017-05-16 | 2018-05-16 | 白金耐性癌の治療 |
| JP2023018285A Active JP7658995B2 (ja) | 2017-05-16 | 2023-02-09 | 白金耐性癌の治療 |
| JP2025052922A Pending JP2025098190A (ja) | 2017-05-16 | 2025-03-27 | 白金耐性癌の治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562653A Active JP7627393B2 (ja) | 2017-05-16 | 2018-05-16 | 白金耐性癌の治療 |
| JP2023018285A Active JP7658995B2 (ja) | 2017-05-16 | 2023-02-09 | 白金耐性癌の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20200352945A1 (https=) |
| EP (1) | EP3624803A1 (https=) |
| JP (3) | JP7627393B2 (https=) |
| KR (2) | KR20240148941A (https=) |
| CN (1) | CN110603042A (https=) |
| AR (1) | AR111803A1 (https=) |
| AU (2) | AU2018268400B2 (https=) |
| GB (1) | GB201707864D0 (https=) |
| MX (2) | MX2019013665A (https=) |
| NZ (1) | NZ758037A (https=) |
| SG (1) | SG11201909859RA (https=) |
| TW (1) | TW201900176A (https=) |
| WO (1) | WO2018211433A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55818A (fr) | 2019-04-29 | 2022-03-16 | Immunogen Inc | Anticorps et immunoconjugués de fr-alpha biparatopique |
| EP4347661A4 (en) * | 2021-06-04 | 2025-06-18 | ImmunoGen, Inc. | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA |
| WO2024097784A2 (en) * | 2022-11-03 | 2024-05-10 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for treating refractory cancers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121214D0 (en) | 2001-08-31 | 2001-10-24 | Btg Int Ltd | Synthetic method |
| KR20100043294A (ko) | 2001-08-31 | 2010-04-28 | 비티지 인터내셔널 리미티드 | 항암제로서 사용되는 시클로펜타[ｇ]퀴나졸린 화합물 |
| US7528141B2 (en) * | 2001-08-31 | 2009-05-05 | Btg International Limited | Use of cyclopenta[g]quinazoline derivatives for treating cancer |
| CN101977620B (zh) * | 2008-03-18 | 2014-05-07 | 英国技术集团国际有限公司 | 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物 |
| EA201291302A1 (ru) | 2010-07-19 | 2013-09-30 | Оникс Фармасьютикалз, Инк. | Синтез циклопентахиназолинов |
| HUE028918T2 (en) | 2010-12-22 | 2017-01-30 | Btg Int Ltd | Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt |
-
2017
- 2017-05-16 GB GBGB1707864.3A patent/GB201707864D0/en not_active Ceased
-
2018
- 2018-05-16 WO PCT/IB2018/053428 patent/WO2018211433A1/en not_active Ceased
- 2018-05-16 TW TW107116652A patent/TW201900176A/zh unknown
- 2018-05-16 KR KR1020247032300A patent/KR20240148941A/ko active Pending
- 2018-05-16 MX MX2019013665A patent/MX2019013665A/es unknown
- 2018-05-16 AR ARP180101299A patent/AR111803A1/es unknown
- 2018-05-16 US US16/613,912 patent/US20200352945A1/en not_active Abandoned
- 2018-05-16 SG SG11201909859R patent/SG11201909859RA/en unknown
- 2018-05-16 EP EP18730117.1A patent/EP3624803A1/en active Pending
- 2018-05-16 JP JP2019562653A patent/JP7627393B2/ja active Active
- 2018-05-16 CN CN201880030434.2A patent/CN110603042A/zh active Pending
- 2018-05-16 KR KR1020197032543A patent/KR20200003811A/ko not_active Ceased
- 2018-05-16 NZ NZ758037A patent/NZ758037A/en unknown
- 2018-05-16 AU AU2018268400A patent/AU2018268400B2/en active Active
-
2019
- 2019-11-14 MX MX2023005295A patent/MX2023005295A/es unknown
-
2020
- 2020-03-05 US US16/810,160 patent/US11026948B2/en active Active
-
2021
- 2021-05-03 US US17/306,052 patent/US12128045B2/en active Active
-
2023
- 2023-02-09 JP JP2023018285A patent/JP7658995B2/ja active Active
-
2024
- 2024-08-02 AU AU2024205462A patent/AU2024205462B2/en active Active
- 2024-09-23 US US18/893,063 patent/US20250152587A1/en active Pending
-
2025
- 2025-03-27 JP JP2025052922A patent/JP2025098190A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025098190A5 (https=) | ||
| US11576895B2 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| JP2022121594A5 (https=) | ||
| US11033519B2 (en) | Drug combination with antitumor effects | |
| CN108892700B (zh) | 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用 | |
| CN101332301A (zh) | 一种抗肿瘤组合物及其应用 | |
| JP2022544559A5 (https=) | ||
| CN105147654A (zh) | 一种将白藜芦醇和二甲双胍组合用于抗肿瘤药物 | |
| WO2024028846A1 (en) | Combination therapy for treating cancers | |
| WO2021159547A1 (zh) | 一种预防和/或治疗卵巢癌的多肽药物及其用途 | |
| WO2024198712A1 (zh) | 一种应用于肝癌治疗的寡核苷酸药物制剂及其制备方法和应用 | |
| WO2009096245A9 (ja) | 医薬組成物又は組合せ剤 | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| CN118717798A (zh) | 一种提高肿瘤化疗效果的药物及氢分子在制备用于提高肿瘤化疗效果药物中的应用 | |
| JP2024514506A5 (https=) | ||
| CN111265665B (zh) | 一种治疗宫颈癌的药物组合物及其制药用途 | |
| CN102319260A (zh) | 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用 | |
| CN107200769A (zh) | 一种具有防治肿瘤转移作用的救必应酸衍生物 | |
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| CN121197332A (zh) | 康莱特注射液作为索拉非尼的增效剂在制备肝癌药物中的应用 | |
| JPS6337767B2 (https=) | ||
| EP2560638A2 (en) | Method of treating gastric cancer | |
| RU2022106182A (ru) | Тетрациклические соединения и их соли, составы и способы их применения | |
| Adewole et al. | P1-009: a clinico pathologic features and management of lung cancer in a Nigeria | |
| JP2007522236A5 (https=) |